Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis

Neuroscience Letters

Volumn 612, Issue , 2016, Pages 193-198

  Chen, Song ^a   Yin, Lei ^a   Xu, Zheng ^a   An, Feng Mao ^a   Liu, Ai Ran ^b   Wang, Ying ^a   Yao, Wen Bing ^a   Gao, Xiang Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Diabetes; Glucagon like peptide 1 receptor; Oxidative stress; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; CASPASE 9; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; EXENDIN 4; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CYTOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; TUMOR CELL LINE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MICE, INBRED ICR; NADPH OXIDASE; NEURONS; NF-KAPPA B; OXIDATIVE STRESS; PEPTIDES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; VENOMS;

EID: 84955509015     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.12.007     Document Type: Article

References (33)

1. Jayaraman A., Pike C.J. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr. Diabetes Rep. 2014, 14:1-9.
2. Vignini A., Giulietti A., Nanetti L., Raffaelli F., Giusti L., Mazzanti L., Provinciali L. Alzheimers disease and diabetes: new insights and unifying therapies. Curr. Diabetes Rev. 2013, 9:218-227.
3. Ott A., Stolk R., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia the Rotterdam study. Neurology 1999, 53:1937-1942.
4. Strachan M.W., Reynolds R.M., Marioni R.E., Price J.F. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 2011, 7:108-114.
5. Li J., Liu D., Sun L., Lu Y., Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 2012, 317:1-5.
6. Butterfield D.A., Di Domenico F., Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. BBA-Mol. Basis Dis. 2014, 1842:1693-1706.
7. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014, 221:T31-T41.
8. Hamilton A., Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
9. Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., Harrington M.G., Chui H.C., Law M., Zlokovic B.V. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
10. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
11. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13:33.
12. Kastin A., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. 2003, 27:313-318.
13. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219.
14. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. AGE 2012, 34:1211-1224.
15. Chen S., An F.M., Yin L., Liu A.R., Yin D.K., Yao W.B., Gao X.D. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 2014, 256:137-146.
16. Li Y., Tweedie D., Mattson M.P., Holloway H.W., Greig N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 2010, 113:1621-1631.
17. Liu R., Wu C.X., Zhou D., Yang F., Tian S., Zhang L., Zhang T.T., Du G.H. Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC Med. 2012, 10:105.
18. Jiang F., Zhang Y., Dusting G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol. Rev. 2011, 63:218-242.
19. Ko S.Y., Lin Y.P., Lin Y.S., Chang S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic. Biol. Med. 2010, 49:474-480.
20. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Münch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 2011, 32:763-777.
21. Xie J., Méndez J.D., Méndez-Valenzuela V., Aguilar-Hernández M.M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013, 25:2185-2197.
22. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9:907-913.
23. Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., Thiyagarajan M., Zarcone T., Fritz G., Friedman A.E., Miller B.L., Zlokovic B.V. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 2012, 122:1377-1392.
24. Yan S.S., Chen D., Yan S., Guo L., Du H., Chen J.X. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front. Biosci. (Schol. Ed.) 2012, 4:240-250.
25. Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A., McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D., Hori O., Ogawa S., Stern D.M., Yamada K., Yan S.S. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20021-20026.
26. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging 2012, 33:1400-1410.
27. Guimarães E.L., Empsen C., Geerts A., van Grunsven L.A. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J. Hepatol. 2010, 52:389-397.
28. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255.
29. Yi B., Hu X., Wen Z., Zhang T., Cai Y. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression. Exp. Ther. Med. 2014, 8:1185-1190.
30. Huang H.J., Chen Y.H., Liang K.C., Jheng Y.S., Jhao J.J., Su M.T., Lee-Chen G.J., Hsieh-Li H.M. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PLoS One 2012, 7:e39656.
31. Guglielmotto M., Aragno M., Tamagno E., Vercellinatto I., Visentin S., Medana C., Catalano M.G., Smith M.A., Perry G., Danni O., Boccuzzi G., Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol. Aging 2012, 33:196.e13-196.e27.
32. Zheng Z., Chen H., Li J., Li T., Zheng B., Zheng Y., Jin H., He Y., Gu Q., Xu X. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012, 61:217-228.
33. Ceriello A. The emerging challenge in diabetes: the metabolic memory. Vasc. Pharmacol. 2012, 57:133-138.